Clinical efficacy of 2-week and 3-week albumin-bound paclitaxel therapy for advanced pancreatic cancer | Synapse
March 3, 2026Open Access
Clinical efficacy of 2-week and 3-week albumin-bound paclitaxel therapy for advanced pancreatic cancer
Puntos clave
The albumin-bound paclitaxel therapy did not show a significant difference in clinical efficacy between the two and three-week groups.
The two-week treatment group demonstrated better tolerance and safety compared to the three-week group.
Assessment of nab-PTX was performed across advanced pancreatic cancer cases with similar patient characteristics.
Findings imply the potential for improved patient comfort with the shorter therapy duration.
Resumen
The clinical efficacy of nab-PTX in the 2-week and dose intensive 3 week did not show significant difference, but the 2-week treatment group had better tolerance and safety.